Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vinay Thohan

Advanced Heart Failure and Transplant Cardiology Asheville, NC Medical Doctor

NPI 1184650798 CMS profile 234499

509 Biltmore Ave, Fl 4, Asheville, NC 28801

Open in the dashboard

General payments

$164,164

446 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,942 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Vinay Thohan of Asheville, NC is reported in the CMS Open Payments database as having received $164,164 across 446 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,942 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,139 89
2024 General $23,472 71
2023 General $23,010 81
2022 General $38,260 64
2021 General $38,234 58
2020 General $21,659 52
2019 General $2,391 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vinay Thohan
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Vinay Thohan were reported at $17,139. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Vinay Thohan Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $2,391 $863 $224–$4,562 $163
2020 $21,659 $452 $122–$3,992 $114
2021 $38,234 $550 $159–$3,571 $132
2022 $38,260 $729 $221–$4,357 $149
2023 $23,010 $1,002 $309–$5,827 $160
2024 $23,472 $931 $273–$5,204 $164
2025 $17,139 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $73,586 67 payments
  2. Pfizer Inc. $45,105 59 payments
  3. Impulse Dynamics (USA) Inc. $15,710 27 payments
  4. Lilly USA, LLC $9,900 9 payments
  5. Abbott Laboratories $9,552 152 payments
  6. E.R. Squibb & Sons, L.L.C. $5,507 17 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $1,346 7 payments
  8. Actelion Pharmaceuticals US, Inc. $817 26 payments
  9. Abiomed $593 7 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $392 25 payments
  11. Other $1,656 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $117,946 46 payments
  2. Consulting Fee $15,133 15 payments
  3. Food and Beverage $13,467 356 payments
  4. Travel and Lodging $13,390 21 payments
  5. Honoraria $4,100 2 payments
  6. Education $129 6 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $60,759 47 payments
  2. VYNDAQEL $44,687 50 payments
  3. JARDIANCE Diabetes $12,820 19 payments
  4. JARDIANCE Diabetes $9,900 9 payments
  5. Optimizer Smart System Cardiovascular Device $7,497 11 payments
  6. CAMZYOS $5,312 13 payments
  7. CardioMEMS HF System $4,997 24 payments
  8. OPTIMIZER SMART SYSTEM Cardiovascular Device $4,000 1 payment
  9. Optimizer Cardiovascular $2,983 5 payments
  10. OPTIMIZER Cardiovascular Device $1,230 10 payments
  11. Other $11,216 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

3,856

Median for Cardiology: 2,533

Drug cost

$9,767,373

Median for Cardiology: $485,213

Branded share of claims

41.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 172 $4,019,845
Adempas Riociguat Brand 101 $1,364,044
Tyvaso Dpi Treprostinil Brand 37 $895,786
Opsumit Macitentan Brand 59 $744,712
Orenitram Er Treprostinil Diolamine Brand 49 $587,449
Uptravi Selexipag Brand 21 $436,337
Jardiance Empagliflozin Brand 377 $393,894
Camzyos Mavacamten Brand 42 $337,167
Entresto Sacubitril/Valsartan Brand 258 $320,280
Vyndaqel Tafamidis Meglumine Brand 13 $290,398

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$90,111

Medicare's payments for the services billed

Medicare patients

321

Average age 73

Services billed

1,131

123 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 67%
Atrial fibrillation 58%
Chronic kidney disease 55%
Diabetes 49%
Arthritis 38%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $10,509
$10,509 13 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $9,294
  • Lilly USA, LLC $750
$10,044 377 —
Adempas
  • Bayer HealthCare Pharmaceuticals Inc. $1,141
$1,141 101 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $443
$443 42 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record